Yin Yang-1 inhibits vascular smooth muscle cell growth and intimal thickening by repressing p21WAF1/Cip1 transcription and p21 WAF1/Cip1-Cdk4-Cyclin D1 assembly

Circulation Research

Volumn 101, Issue 2, 2007, Pages 146-155

  Santiago, Fernando S ^a,b   Ishii, Hideto ^a,b   Shafi, Shahida ^c   Khurana, Rohit ^c   Kanellakis, Peter ^d   Bhindi, Ravinay ^a,b   Ramirez, Manfred J ^c   Bobik, Alexander ^d   Martin, John F ^c   Chesterman, Colin N ^a,b   Zachary, Ian C ^c   Khachigian, Levon M ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Arterial injury; Gene expression; Intimal thickening; Vascular biology

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEASOME; PROTEIN P53; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YY1;

ANIMAL CELL; ARTERY INTIMA PROLIFERATION; ARTERY WALL; ARTICLE; BLOOD VESSEL INJURY; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER; UBIQUITINATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIES; CELL LINE; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENE EXPRESSION REGULATION; HUMANS; MULTIPROTEIN COMPLEXES; MYOCYTES, SMOOTH MUSCLE; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN BINDING; RABBITS; RATS; RESPONSE ELEMENTS; RETINOBLASTOMA PROTEIN; SP1 TRANSCRIPTION FACTOR; THYMIDINE KINASE; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; TUNICA INTIMA; YY1 TRANSCRIPTION FACTOR;

EID: 34547580850     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.106.145235     Document Type: Article

References (54)

1. Thomas MJ, Seto E. Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key. Gene. 1999;236:197-208.
2. Shi Y, Lee JS, Galvin KM. Everything you have ever wanted to know about Yin Yang 1. Biochim Biophys Acta. 1997;1332:F49-F66.
3. Shi Y, Seto E, Chang LS, Shenk T. Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell. 1991;67:377-388.
4. Park K, Atchison ML. Isolation of a candidate repressor/activator, NF-E1 (YY1), that binds to the immunoglobulin kappa3′ enhancer and the immunoglobulin heavy chain microE1 site. Proc Natl Acad Sci U S A. 1991;88:9804-9808.
5. Flanagan JR, Becker KG, Ennist DL, Gleason SL, Driggers PH, Levi BZ, Appella E, Ozato K. Cloning of a negative transcription factor that binds to the upstream conserved region of Moloney murine leukemia virus. Mol Cell Biol. 1992;12:38-44.
6. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene. 2006;25:1125-1142.
7. Affar el B, Gay F, Shi Y, Liu H, Huarte M, Wu S, Collins T, Li E. Essential dosage-dependent functions of the transcription factor yin yang 1 in late embryonic development and cell cycle progression. Mol Cell Biol. 2006;26:3565-3581.
8. Santiago FS, Lowe HC, Bobryshev YV, Khachigian LM. Induction of the transcriptional repressor Yin Yang-1 by vascular cell injury: autocrine/paracrine role of endogenous fibroblast growth factor-2. J Biol Chem. 2001;276:41143-41149.
9. Wang CC, Chen JJ, Yang PC. Multifunctional transcription factor YY1: a therapeutic target in human cancer. Expert Opin Ther Targets. 2006;10:253-266.
10. Dashwood MR, Anand R, Loesch A, Souza DS. Hypothesis: a potential role for the vasa vasorum in the maintenance of vein graft patency. Angiology. 2004;55:385-395.
11. Khurana R, Shafi S, Martin J, Zachary I. Vascular endothelial growth factor gene transfer inhibits neointimal macrophage accumulation in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol. 2004;24:1074-1080.
12. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. Lab Invest. 1983;49:327-333.
13. Kavurma MM, Khachigian LM. Sp1 inhibits proliferation and induces apoptosis in vascular smooth muscle cells by repressing p21WAF1/Cip1 transcription and cyclin D1/Cdk4/p21WAF1/Cip1 complex formation. J Biol Chem. 2003;278:32537-32543.
14. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501-1512.
15. Shrivastava A, Calame K. An analysis of genes regulated by the multifunctional transcriptional regulator Ying Yang-1. Nucleic Acids Res. 1994;22:5151-5155.
16. Watanabe M, Sakomura Y, Kurabayashi M, Manabe I, Aikawa M, Kuro-o M, Suzuki T, Yazaki Y, Nagai R. Structure and characterization of the 5′-flanking region of the mouse smooth muscle myosin heavy chain (SM1/2) gene. Circ Res. 1996;78:978-989.
17. Hoppe KL, Francone OL. Binding and functional effects of transcription factors Sp1 and Sp3 on the proximal human lecithin:cholesterol acyltransferase promoter. J Lipid Res. 1998;39:969-977.
18. Seto E, Lewis B, Shenk T. Interaction between transcription factors Sp1 and YY1. Nature. 1993;365:462-464.
19. Lee J-S, Galvin KM, Shi Y. Evidence for physical interaction between the zinc-finger transcription factors YY1 and Sp1. Proc Natl Acad Sci U S A. 1993;90:6145-6149.
20. Khachigian LM, Field SE, Crouch R, Chesterman CN. Platelet-derived growth factor A-chain synthetic peptide inhibits human glioma xenograft proliferation in nude mice. Anticancer Research. 1995;15:337-342.
21. Kavurma MM, Khachigian LM. Vascular smooth muscle cell-specific regulation of cyclin-dependent kinase inhibitor p21WAF1/Cip1 transcription by Sp1 is mediated via distinct cis-acting positive and negative regulatory elements in the proximal p21WAF1/Cip1 promoter. J Cell Biochem. 2004;93:904-916.
22. Li HX, Lei DS, Wang XQ, Skog S, He Q. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncol Rep. 2005;13:145-149.
23. Tommasi S, Pfeifer GP. Constitutive protection of E2F recognition sequences in the human thymidine kinase promoter during cell cycle progression. J Biol Chem. 1997;272:30483-30490.
24. El-Deiry W, Tokino T, Velulescu V, Levy D, Parsons R, Trent J, Lin D, Mercer W, Kinzler K, Vogelstein B. Waf1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
25. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296-299.
26. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387:299-303.
27. Sui G, Affar el B, Shi Y, Brignone C, Wall NR, Yin P, Donohoe M, Luke MP, Calvo D, Grossman SR. Yin Yang 1 is a negative regulator of p53. Cell. 2004;117:859-872.
28. Halaban R, Cheng E, Zhang Y, Mandigo CE, Miglarese MR. Release of cell cycle contrainst in mouse melanocytes by overexpressed mutant E2F1E132, but not by deletion of p16INK4A or p21Waf1/Cip1. Oncogene. 1998;16:2489-2501.
29. Kivinen L, Laiho M. Ras- and mitogen-activated protein kinase kinase-dependent and -independent pathways in p21Cip1/Waf1 induction by fibroblast growth factor-2, platelet-derived growth factor, and transforming growth factor-β1. Cell Growth Differ. 1999;10:621-628.
30. Zhan Y, Kim S, Izumi Y, Izumiya Y, Nakao T, Miyazaki H, Iwao H. Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Arterioscler Thromb Vasc Biol. 2003;23:795-801.
31. Yang ZY, Simari RD, Perkins ND, San H, Gordon D, Nabel GJ, Nabel EG. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc Natl Acad Sci U S A. 1996;93:7905-7910.
32. Chung JK, Lee T, Jung IM, Kim YK, Min SK, Suh JW, Kim SJ. Expression of cell cycle regulators during smooth muscle cell proliferation after balloon catheter injury of rat artery. J Korean Med Sci. 2004;19:327-332.
33. Braun-Dullaeus RC, Mann MJ, Seay U, Zhang L, von Der Leyen HE, Morris RE, Dzau VJ. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol. 2001;21:1152-1158.
34. Perkins ND. Not just a CDK inhibitor: regulation of transcription by p21(WAF1/CIP1/SDI1). Cell Cycle. 2002;1:39-41.
35. Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 1994;8:1750-1758.
36. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997;11:847-862.
37. Weiss RH, Joo A, Randour C. p21(Waf1/Cip1) is an assembly factor required for platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem. 2000;275:10285-10290.
38. Merched AJ, Chan L. Absence of p21Waf1/Cip1/Sdi1 modulates macrophage differentiation and inflammatory response and protects against atherosclerosis. Circulation. 2004;110:3830-3841.
39. Andres V. Unexpected proatherogenic properties of p21: beyond cell cycle control? Circulation. 2004;110:3749-3752.
40. Schlisio S, Halperin T, Vidal M, Nevins JR. Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. Embo J. 2002;21:5775-5786.
41. Wu F, Lee AS. YY1 as a regulator of replication-dependent hamster histone H3.2 promoter and an interactive partner of AP-2. J Biol Chem. 2001;276:28-34.
42. Shrivastava A, Yu J, Artandi S, Calame K. YY1 and c-Myc associate in vivo in a manner that depends on c-Myc levels. Proc Natl Acad Sci U S A. 1996;93:10638-10641.
43. Sawa C, Yoshikawa T, Matsuda-Suzuki F, Delehouzee S, Goto M, Watanabe H, Sawada J, Kataoka K, Handa H. YEAF1/RYBP and YAF-2 are functionally distinct members of a cofactor family for the YY1 and E4TF1/hGABP transcription factors. J Biol Chem. 2002;277:22484-22490.
44. Austen M, Luscher B, Luscher-Firzlaff JM. Characterization of the transcriptional regulator YY1. The bipartite transactivation domain is independent of interaction with the TATA box-binding protein, transcription factor IIB, TAFII55, or cAMP-responsive element-binding protein (CPB)-binding protein. J Biol Chem. 1997;272:1709-1717.
45. Usheva A, Shenk T. TATA-binding protein-independent initiation: YY1, TFIIB, and RNA polymerase II direct basal transcription on supercoiled template DNA. Cell. 1994;76:1115-1121.
46. Monajemi H, Arkenbout EK, Pannekoek H. Gene expression in atherogenesis. Thromb Haemost. 2001;86:404-412.
47. Hautmann MB, Adam PJ, Owens GK. Similarities and differences in smooth muscle α-actin induction by TGF-β in smooth muscle versus non-smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:2049-2058.
48. Rezai-Zadeh N, Zhang X, Namour F, Fejer G, Wen YD, Yao YL, Gyory I, Wright K, Seto E. Targeted recruitment of a histone H4-specific methyltransferase by the transcription factor YY1. Genes Dev. 2003;17:1019-1029.
49. He G, Margolis DM. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol. 2002;22:2965-2973.
50. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767-801.
51. Sata M, Takahashi A, Tanaka K, Washida M, Ishizaka N, Ako J, Yoshizumi M, Ouchi Y, Taniguchi T, Hirata Y, Yokoyama M, Nagai R, Walsh K. Mouse genetic evidence that tranilast reduces smooth muscle cell hyperplasia via a p21(WAF1)-dependent pathway. Arterioscler Thromb Vasc Biol. 2002;22:1305-1309.
52. Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, Feres F, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation. 2003;107:381-383.
53. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localised hypersensitivity and late coronary thrombosis secondary to a Sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-705.
54. Hiatt BL, Ikeno F, Yeung AC, Carter AJ. Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail. Catheter Cardiovasc Interv. 2002;55:409-417.